Story perspectives

Michigan Advances 340B Reform Amid Healthcare Cost Debate

1/30/2026

Summary

Story summary

The Michigan House Health Policy Committee advanced HB 4878 to reform the 340B drug pricing program.
The bill has sparked debate between hospitals and pharmaceutical companies over reporting requirements.
The National Association of Manufacturers (NAM) seeks reforms to reduce healthcare costs and increase transparency in pharmacy benefit managers.
CMS proposed changes to Medicare Advantage that could curb overcharges, prompting mixed reactions from insurers and health policy experts.

History

Historical Context

The Affordable Care Act of 2010 expanded the 340B drug pricing program, enabling eligible hospitals to purchase medications at reduced prices. In 2015, a Kaiser Family Foundation survey revealed that 77% of Americans blamed drug company profits for high prescription costs. Ongoing debates, such as those surrounding HB 4878, highlight persistent tensions between hospitals and pharmaceutical companies over pricing transparency and patient access.

1 of 2

Story summary

The Michigan House Health Policy Committee advanced HB 4878 to reform the 340B drug pricing program.
The bill has sparked debate between hospitals and pharmaceutical companies over reporting requirements.
The National Association of Manufacturers (NAM) seeks reforms to reduce healthcare costs and increase transparency in pharmacy benefit managers.
CMS proposed changes to Medicare Advantage that could curb overcharges, prompting mixed reactions from insurers and health policy experts.

1 / 2